Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Return on Capital Employed (2022 - 2025)

Historic Return on Capital Employed for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 0.31%.

  • ARS Pharmaceuticals' Return on Capital Employed fell 100.0% to 0.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.31%, marking a year-over-year decrease of 100.0%. This contributed to the annual value of 0.01% for FY2024, which is 2500.0% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Return on Capital Employed stood at 0.31% for Q3 2025, which was down 100.0% from 0.22% recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Return on Capital Employed registered a high of 0.01% during Q4 2024, and its lowest value of 0.31% during Q3 2025.
  • In the last 4 years, ARS Pharmaceuticals' Return on Capital Employed had a median value of 0.25% in 2023 and averaged 0.22%.
  • In the last 5 years, ARS Pharmaceuticals' Return on Capital Employed plummeted by -1500bps in 2023 and then skyrocketed by 2700bps in 2024.
  • ARS Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.13% in 2022, then tumbled by -116bps to 0.28% in 2023, then soared by 96bps to 0.01% in 2024, then tumbled by -2529bps to 0.31% in 2025.
  • Its last three reported values are 0.31% in Q3 2025, 0.22% for Q2 2025, and 0.09% during Q1 2025.